Premium
Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications
Author(s) -
Wu Rongzhen,
Chen Hongyu,
Chang Ninghui,
Xu Yuzhi,
Jiao Jiao,
Zhang Hailong
Publication year - 2020
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201903128
Subject(s) - bryostatin 1 , computer science , drug discovery , portfolio , computational biology , biology , bioinformatics , business , genetics , protein kinase c , phosphorylation , finance
Abstract Bryostatins are a class of naturally occurring macrocyclic lactones with a unique fast developing portfolio of clinical applications, including treatment of AIDS, Alzheimer's disease, and cancer. This comprehensive account summarizes the recent progress (2014–present) in the development of bryostatins, including their total synthesis and biomedical applications. An emphasis is placed on the discussion of bryostatin 1 , the most‐studied analogue to date. This review highlights the synthetic and biological challenges of bryostatins and provides an outlook on their future development.